The Chemours Company
NYSE:CCChemicals - Specialty
-$0.27 today
- Market cap
- $1.82B
- Beta
- 1.39
- P/E (TTM)
- -8.0
- EPS (TTM)
- -$2.73
- Dividend yield
- 1.61%
Volume 2.86M
Average 2.80M
CC Operating Income
Profit from core operations after operating expenses, before interest and taxes.
The Chemours CompanyNYSE: CC
Operating Income · Q2 FY2026 · quarter ended Jun 2026
Operating income turns negative
Q2 FY2026 operating income was -$213M, compared with $72M a year earlier. Trailing-twelve-month operating income was -$304M.
Context
- Operating income amounted to 0.1% of revenue in FY2025, down 7.6 pp from a year earlier.
- Operating income increased in 1 of the last 3 fiscal years.
What to watch
Whether operating income reaches the consensus estimate from 7 analysts of $397.83M (+8056.6%) for the fiscal year ending Dec 2026, a step up from the -101.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$213M-432.8% QoQ
- Last fiscal yearDec 2025
- -$5M-101.1% YoY
- LTMJun 2026
- -$304M-187.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -395.8% | +13.7% | +409.5 pp |
| 1 year | -101.1% | +8056.6% | +8157.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (5M) USD
- Year-over-year change
- -101.1%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (5M) | -101.1% |
| FY2024 | 2024-12-31 | 443M | +460.2% |
| FY2023 | 2023-12-31 | (123M) | -115.6% |
| FY2022 | 2022-12-31 | 786M | +16.6% |
| FY2021 | 2021-12-31 | 674M | — |
Operating Income vs competitors
How CC compares with its peers on the latest reported figures
- CC's LTM Jun 2026 operating income of -$304M is the 18th highest of the 19 companies compared; the peer median is $206.55M.
- Its year-over-year change of -187.6% is the 17th highest of 19, against a peer median of +16.9%.
- Operating income amounts to 5.2% of revenue for CC, versus a peer median of 11.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $9.61B | +7.5% | +12.7% | 27.1% | |
| LTM Sep 2026 | $2.81B | +396.9% | — | 8.8% | |
| LTM Jun 2026 | $2.05B | -3.7% | +9.2% | 12.5% | |
| LTM Jun 2026 | $776M | +335.9% | — | 7.8% | |
| LTM Jun 2026 | $682M | -11.3% | +21.8% | 13.2% | |
| LTM Jun 2026 | $501M | -21.0% | +16.9% | 13.8% | |
| LTM Aug 2026 | $409.65M | +16.4% | +7.4% | 11.5% | |
| LTM Sep 2026 | $408.7M | +17.6% | +1.7% | 11.7% | |
| LTM Jun 2026 | $239.32M | +17.5% | +1.7% | 14.0% | |
| LTM Sep 2026 | $173.78M | +197.0% | +50.1% | 8.6% | |
| LTM Jun 2026 | $135M | +51.7% | — | 7.3% | |
| LTM Mar 2026 | $96.44M | +14.4% | -9.1% | 11.8% | |
| LTM Sep 2026 | $86.04M | +170.6% | -3.0% | 5.7% | |
| LTM Mar 2026 | $81.3M | -43.1% | -20.2% | 4.5% | |
| LTM Sep 2026 | -$40.9M | +95.3% | — | 0.3% | |
| LTM Mar 2026 | -$43.88M | -190.2% | — | 39.8% | |
| LTM Jun 2026 | -$227.43M | -191.7% | — | 30.0% | |
| LTM Jun 2026 | -$304M | -187.6% | — | 5.2% | |
| LTM Sep 2026 | -$418M | +50.3% | — | 3.7% | |
| Peer median (excluding CC) | $206.55M | +16.9% | +7.4% | 11.6% | |
Competitors are the stored peer set for CC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.35B | 6.83B | 6.08B | 5.78B | 5.81B |
| Cost of Revenue | 4.96B | 5.22B | 4.77B | 4.63B | 4.91B |
| Gross Profit | 1.38B | 1.62B | 1.31B | 1.15B | 902M |
| Gross Margin | 21.8% | 23.7% | 21.5% | 19.9% | 15.5% |
| Research & Development | 107M | 118M | 108M | 109M | 108M |
| Selling, General & Admin | 592M | 710M | 1.29B | 585M | 799M |
| Operating Expenses | 707M | 830M | 1.43B | 708M | 907M |
| Depreciation & Amortization | 317M | 291M | 307M | 301M | 340M |
| EBITDA | 1.18B | 1.2B | 197M | 692M | 332M |
| EBITDA Margin | 18.6% | 17.5% | 3.2% | 12.0% | 5.7% |
| Operating Income | 674M | 786M | (123M) | 443M | (5M) |
| Operating Margin | 10.6% | 11.5% | -2.0% | 7.7% | -0.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 185M | 163M | 208M | 264M | 269M |
| Other Income / Expenses | 2M | (45M) | (195M) | (316M) | (272M) |
| Income Before Tax | 676M | 741M | (318M) | 127M | (277M) |
| Pre-Tax Margin | 10.7% | 10.8% | -5.2% | 2.2% | -4.8% |
| Income Tax Expense | 68M | 163M | (81M) | 41M | 109M |
| Net Income | 608M | 578M | (238M) | 86M | (386M) |
| Net Margin | 9.6% | 8.5% | -3.9% | 1.5% | -6.6% |
| EPS (Basic) | 3.69 | 3.72 | (1.60) | 0.58 | (2.57) |
| EPS (Diluted) | 3.60 | 3.65 | (1.60) | 0.57 | (2.56) |
| Weighted Avg Shares | 164.94M | 155.36M | 148.91M | 149.49M | 150.35M |
| Weighted Avg Shares (Diluted) | 168.7M | 158.3M | 148.91M | 150.01M | 150.55M |
The Chemours Company
NYSE:CC
Intrinsic Alpha fair value
Locked
Current Price
$12.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.